康美药业
(600518)
| 流通市值：273.68亿 | | | 总市值：273.81亿 |
| 流通股本：138.22亿 | | | 总股本：138.29亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,959,603,514.66 | 2,577,397,097.25 | 1,299,297,937.56 | 5,189,137,199.65 |
| 营业收入 | 3,959,603,514.66 | 2,577,397,097.25 | 1,299,297,937.56 | 5,189,137,199.65 |
| 二、营业总成本 | 4,028,487,323.58 | 2,612,345,435.82 | 1,305,063,457.12 | 5,506,253,760.75 |
| 营业成本 | 3,204,602,637.88 | 2,091,882,757.44 | 1,063,818,220.72 | 4,422,148,257.54 |
| 税金及附加 | 37,110,255.98 | 22,958,613.77 | 11,753,161.29 | 67,684,265.66 |
| 销售费用 | 385,739,589.26 | 241,966,448.24 | 105,570,591 | 416,996,237.36 |
| 管理费用 | 367,816,518.44 | 237,175,089.14 | 114,208,004.44 | 542,785,988.27 |
| 研发费用 | 32,691,882.64 | 17,912,407.27 | 9,309,319.31 | 51,456,445.7 |
| 财务费用 | 526,439.38 | 450,119.96 | 404,160.36 | 5,182,566.22 |
| 其中:利息费用 | 4,944,162.84 | 3,128,868.69 | 1,671,114.63 | 21,387,136.02 |
| 其中:利息收入 | 5,576,587.76 | 3,366,514.32 | 1,558,858.43 | 17,227,545.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,438.11 | -919.26 | -1,196.03 | -1,838.54 |
| 加:投资收益 | 27,367,448.37 | 231,879.41 | 134,200.11 | 59,181,059.28 |
| 资产处置收益 | 2,038,103.48 | 286,015.92 | 255,529.68 | 39,470,945.23 |
| 资产减值损失(新) | -798,496.74 | -798,690.5 | -1,755,298.11 | -142,740,044.03 |
| 信用减值损失(新) | 39,160,071.24 | 42,034,577.77 | 10,214,764.89 | -1,130,016.33 |
| 其他收益 | 32,838,029.09 | 22,800,164.59 | 10,008,219.2 | 337,548,057.16 |
| 四、营业利润 | 31,731,784.63 | 29,604,689.36 | 13,090,700.18 | -24,788,398.33 |
| 加:营业外收入 | 3,243,803.6 | 606,841.51 | 667,556.16 | 78,995,366.14 |
| 减:营业外支出 | 4,382,544.78 | 1,689,620.99 | 1,076,256.6 | 19,556,527.93 |
| 五、利润总额 | 30,593,043.45 | 28,521,909.88 | 12,681,999.74 | 34,650,439.88 |
| 减:所得税费用 | 15,501,919.69 | 10,206,256 | 3,713,329.01 | 22,568,241.16 |
| 六、净利润 | 15,091,123.76 | 18,315,653.88 | 8,968,670.73 | 12,082,198.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 15,091,123.76 | 18,315,653.88 | 8,968,670.73 | 12,082,198.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 13,082,309.31 | 16,901,389.86 | 8,505,782.8 | 8,573,662.73 |
| 少数股东损益 | 2,008,814.45 | 1,414,264.02 | 462,887.93 | 3,508,535.99 |
| 扣除非经常损益后的净利润 | -37,936,716.64 | -3,618,595.24 | -2,572,527.89 | -533,384,001.89 |
| 七、每股收益 | | | | |
| 八、其他综合收益 | -69,577.23 | -30,319.91 | - | -164,285.8 |
| 归属于母公司股东的其他综合收益 | -69,577.23 | -30,319.91 | - | -164,285.8 |
| 九、综合收益总额 | 15,021,546.53 | 18,285,333.97 | 8,968,670.73 | 11,917,912.92 |
| 归属于母公司股东的综合收益总额 | 13,012,732.08 | 16,871,069.95 | 8,505,782.8 | 8,409,376.93 |
| 归属于少数股东的综合收益总额 | 2,008,814.45 | 1,414,264.02 | 462,887.93 | 3,508,535.99 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-30 | 2025-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |